Stocktoria
NANOVIRICIDES, INC. NNVC
NYSE American · XASE · stock · Pharmaceutical Preparations · website · IPO 2004-08-12
NANOVIRICIDES, INC. financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — | — | — | — | — | — | — |
| R&D expense | $5.5M | $5.4M | $6.4M | $5.8M | $6.1M | $4.7M | $5.9M | $5.9M | $6.6M | $5.0M |
| Operating income | -$9.6M | -$8.5M | -$8.9M | -$8.1M | -$8.7M | -$8.0M | -$8.7M | -$9.3M | -$9.6M | -$8.9M |
| Interest expense | — | — | $938 | $5,123 | $85,405 | $93,670 | $0 | $185,274 | $780,767 | $1.0M |
| Income tax | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Net income | -$9.5M | -$8.3M | -$8.6M | -$8.1M | -$8.8M | -$13.4M | -$8.4M | -$8.6M | -$10.3M | -$10.7M |
| EPS (diluted) | $-0.63 | $-0.70 | $-0.74 | $-0.70 | $-0.81 | — | — | $-0.13 | $-0.17 | $-0.19 |
| Operating cash flow | -$8.5M | -$6.3M | -$5.7M | -$5.9M | -$8.2M | -$6.7M | -$6.8M | -$7.8M | -$7.9M | -$6.8M |
| Free cash flow | -$8.5M | -$6.5M | -$5.8M | -$6.2M | -$8.5M | -$6.7M | -$6.9M | -$8.0M | -$8.1M | -$7.3M |
| Cash & equivalents | $1.6M | $4.8M | $8.1M | $14.1M | $20.5M | $13.7M | $2.6M | $7.1M | $15.1M | $24.2M |
| Total assets | $8.8M | $12.8M | $16.9M | $23.5M | $30.3M | $23.9M | $13.4M | $18.5M | $27.0M | $36.6M |
| Total liabilities | $1.3M | $1.4M | $2.0M | $412,837 | — | — | — | $881,948 | $6.7M | $13.6M |
| Shareholders' equity | $7.5M | $11.5M | $14.9M | $23.1M | $29.9M | $21.8M | $10.6M | $17.7M | $20.3M | $23.0M |
Source: SEC EDGAR filings · CIK 0001379006 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.